

Prenatal exposure to environmental contaminants is associated with altered cord serum metabolite profiles in future immune-mediated diseases

Bagavathy Shanmugam Karthikeyan,^{1,2} Tuulia Hyötyläinen,¹ Tannaz Ghaffarzadegan,¹ Eric Triplett,³ Matej Orešič,^{2,4,*} Johnny Ludvigsson⁵

¹School of Science and Technology, Örebro University, SE-702 81 Örebro, Sweden

²School of Medical Sciences, Faculty of Medicine and Health, Örebro University, SE-702 81 Örebro, Sweden

³Department of Microbiology and Cell Science, Institute of Food and Agricultural Sciences University of Florida, Gainesville, 32611-0700, FL, USA

⁴Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, FI-20520, Finland

⁵Crown Princess Victoria's Children's Hospital and Division of Pediatrics, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, SE-581 85, Sweden

*Correspondence:

Matej Orešič; School of Science and Technology, Örebro University, 702 81 Örebro, Sweden.
Email: matej.oresic@oru.se; Phone: +46 76 9464459. ORCID ID: 0000-0002-2856-9165
(editorial correspondence)

24 Abstract

25 Prenatal exposure to environmental contaminants is a significant health concern because it has the
 26 potential to interfere with host metabolism, leading to adverse health effects in early childhood
 27 and later in life. Growing evidence suggests that genetic and environmental factors, as well as their
 28 interactions, play a significant role in the development of autoimmune diseases. In this study, we
 29 hypothesized that prenatal exposure to environmental contaminants impacts cord serum
 30 metabolome and contributes to the development of autoimmune diseases. We selected cord serum
 31 samples from All Babies in Southeast Sweden (ABIS) general population cohort, from infants who
 32 later developed one or more autoimmune-mediated and inflammatory diseases: celiac disease
 33 (CD), Crohn's disease (IBD), hypothyroidism (HT), juvenile idiopathic arthritis (JIA), and type 1
 34 diabetes (T1D) (all cases, N = 62), along with matched controls (N = 268). Using integrated
 35 exposomics and metabolomics mass spectrometry (MS) based platforms, we determined the levels
 36 of contaminants and metabolites. Differences in exposure levels were found between the controls
 37 and those who later developed various diseases. High contaminant exposure levels were associated
 38 with changes in metabolome, including amino acids and free fatty acids. Specifically, we identified
 39 marked associations between metabolite levels and exposure levels of deoxynivalenol (DON),
 40 bisphenol S (BPS), and specific per- and polyfluorinated substances (PFAS). Our study suggests
 41 that prenatal exposure to specific environmental contaminants alters the cord serum metabolomes,
 42 which, in turn, might increase the risk of various immune-mediated disease later in life.

43

44 **Keywords:** autoimmune disease; environmental contaminants; exposome; lipidomics;
 45 metabolomics; type 1 diabetes.

46

47 Introduction

48 Exposure to environmental contaminants contributes to the global burden of many chronic diseases
 49 (Chew et al. 2023; Cui et al. 2016; Diseases and Injuries 2020; Landrigan et al. 2016; Shaffer et
 50 al. 2019). Over the past few decades, the prevalence of autoimmune diseases increased in both
 51 developed and developing countries, resulting in a high disease burden (Berhan et al. 2011;
 52 Carstensen et al. 2020; Eaton et al. 2007; Harjutsalo et al. 2013; Patterson et al. 2009).
 53 Autoimmune diseases are often manifested in early childhood and are also common among the
 54 pregnant mothers (Eaton et al. 2007; Tincani et al. 2016). They are chronic, impact child growth
 55 and development and require long-term management and care (Rosenblum et al. 2012; Wilson et
 56 al. 2016). Many studies suggest that a combination of genetic predisposition, environmental and
 57 maternal factors as well as their interactions play a significant role in the etiology of autoimmune
 58 diseases (Ellis et al. 2014; Oresic et al. 2013; Oresic et al. 2008; Rewers and Ludvigsson 2016;
 59 Sen et al. 2019; Sen et al. 2020; Sinisalu et al. 2020; Virolainen et al. 2023).

60 Exposure of humans to environmental chemicals begins already during the "sensitive window" of
 61 human early development, including the prenatal stage (Buhimschi and Buhimschi 2012;
 62 Karthikeyan et al. 2021; Landrigan and Goldman 2011; Robinson and Vrijheid 2015). Prenatal
 63 exposure to PFAS and other contaminants have been associated with abnormal metabolism and
 64 later progression to autoimmune diseases such as T1D (McGlinchey et al. 2020), CD (Sen et al.
 65 2019; Sinisalu et al. 2020), IBD (Filimoniuk et al. 2020) later. PFAS exposure, for instance, alters
 66 the levels of phospholipids and contributes to the risk of T1D (McGlinchey et al. 2020). Although
 67 most autoimmune diseases share common pathogenicity and genetic risk factors (Ilonen et al.
 68 2016; Sen et al. 2019), their underlying pathogenic mechanisms are poorly understood. Beside
 69 exposure to environmental chemicals, perinatal factors such as low birth weight (Katsarou et al.
 70 2017), the gut microbiome (Belteky et al. 2023; Khan and Wang 2019; Kindgren et al. 2023; Kostic
 71 et al. 2015; Vatanen et al. 2018; Weis 2018) and maternal diet (Johnson et al. 2021; Johnson et al.
 72 2019; Virtanen et al. 2012) are also attributed to the progression of autoimmune diseases.

Given the potential impact of exposure to environmental contaminants and the role of maternal factors in the progression of autoimmune diseases (Hyotylainen et al. 2023), it is important to characterize the prenatal and early-life exposome to better understand the pathogenesis of autoimmune diseases. Herein, we hypothesized that exposure to environmental contaminants impacts cord serum metabolome, which may contribute to the development of one or more autoimmune diseases in the general population cohort (All Babies In Southeast Sweden, ABIS) (Ludvigsson et al. 2001; Nygren et al. 2015). We quantified levels of contaminants and metabolite profiles from cord serum collected at birth, using integrated exposomics and metabolomics approaches. We investigated (i) the levels of exposure and significant differences between controls and cases, (ii) associations of contaminant exposure with cord serum metabolic profiles, and (iii) the impact of contaminant exposure levels on cord serum metabolic profiles.

Materials and methods

Study design

ABIS, a general population cohort consists of 17000 children born 1st of Oct 1997- 1st of Oct 1999, followed prospectively with regular follow-ups. ABIS is connected to the Swedish National Diagnosis Register which give information about diagnosis of autoimmune disease. Stool samples were collected from ca 1800 individuals at 1 year of age, and microbiome studies have been performed (Belteky et al. 2023; Hyotylainen et al. 2023). The present study includes subjects (N=62) from this group who later developed one or more autoimmune and inflammatory diseases such as celiac disease (CD), Crohns disease (IBD), hypothyroidism (HT), juvenile idiopathic arthritis (JIA) and type1 diabetes (T1D) along with their matching controls (N=268). The cord blood samples collected during birth were subjected to metabolomics analysis. **Fig. 1** summarizes the study design and integrated workflow.

This study was performed in accordance with the Declaration of Helsinki. The ABIS study was approved by the Research Ethics Committees of the Faculty of Health Sciences at Linköping

University, Sweden, 1997/96287 and 2003/03-092 and the Medical Faculty of Lund University, Sweden (DNR 99227, DNR 99321). All participating parents gave their informed consent to participate in ABIS after oral, written and video information. ABIS connection to national register approved by the Research Ethics Committees of the Faculty of Health Sciences at Linköping University, Sweden, DNR 05-513, and 2018/380-32.

Analysis of metabolome and environmental contaminants

A total of 360 cord blood samples were randomized and analyzed as described below. Shortly, two methods were applied for separate extraction of lipids and polar/semipolar metabolites and the extracts were then analyzed using an ultra-high-performance liquid chromatography quadrupole time-of-flight mass spectrometry (UHPLC-QTOFMS) as described previously (Hyotylainen et al. 2023) and the data were processed using MZmine 2.53 (Pluskal et al. 2010). Quantification was performed using calibration curves and the identification was done with a custom data base, with identification levels 1 and 2 (Metabolomics Standards Initiative). Quality control was performed by analyzing pooled quality control samples. In addition, extracted blank samples, standards compounds, and reference plasma (NIST SRM 1950); purchased from the National Institute of Standards and Technology at the US Department of Commerce (Washington, DC, USA)) were analyzed as part of the quality control procedure.

Analysis of molecular lipids

10 µl of serum was mixed with 10 µl 0.9% NaCl and extracted with 120 µl of CHCl₃: MeOH (2:1, v/v) solvent mixture containing internal standard mixture (c = 2.5 µg/ml; 1,2-diheptadecanoyl-sn-glycero-3-phosphoethanolamine (PE(17:0/17:0)), N-heptadecanoyl-D-erythro-sphingosylphosphorylcholine (SM(d18:1/17:0)), N-heptadecanoyl-D-erythro-sphingosine (Cer(d18:1/17:0)), 1,2-diheptadecanoyl-sn-glycero-3-phosphocholine (PC(17:0/17:0)), 1-heptadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine (LPC(17:0)) and 1-palmitoyl-d31-2-oleoyl-sn-glycero-3-phosphocholine (PC(16:0/d31/18:1)) and, triheptadecanoylglycerol

(TG(17:0/17:0/17:0)). The samples were vortexed and let stand on the ice for 30 min before centrifugation (9400 rcf, 3 min). 60 µl of the lower layer of was collected and diluted with 60 µl of CHCl₃: MeOH. The samples were kept at -80 °C until analysis.

Samples were analyzed by UHPLC-QTOFMS (Agilent Technologies; Santa Clara, CA, USA). The analysis was carried out on an ACQUITY UPLC BEH C18 column (2.1 mm × 100 mm, particle size 1.7 µm) by Waters (Milford, USA). The eluent system consisted of (A) 10 mM NH₄Ac in H₂O and 0.1% formic acid and (B) 10 mM NH₄Ac in ACN: IPA (1:1) and 0.1% formic acid. The gradient was as follows: 0-2 min, 35% solvent B; 2-7 min, 80% solvent B; 7-14 min 100% solvent B. The flow rate was 0.4 ml/min.

The following steps were applied in data processing with MZmine 2.53: (i) Mass detection with a noise level of 1000, (ii) Chromatogram builder with a minimum time span of 0.08 min, minimum height of 1000 and a m/z tolerance of 0.006 m/z or 10.0 ppm, (iii) Chromatogram deconvolution using the local minimum search algorithm with a 70% chromatographic threshold, 0.05 min minimum RT range, 5% minimum relative height, 1200 minimum absolute height, a minimum ration of peak top/edge of 1.2 and a peak duration range of 0.08–5.0, (iv), Isotopic peak grouper with a m/z tolerance of 5.0 ppm, RT tolerance of 0.05 min, maximum charge of 2 and with the most intense isotope set as the representative isotope, (v) Join aligner with a m/z tolerance of 0.009 or 10.0 ppm and a weight for of 2, a RT tolerance of 0.15 min and a weight of 1 and with no requirement of charge state or ID and no comparison of isotope pattern, (vi) Peak list row filter with a minimum of 10% of the samples (vii) Gap filling using the same RT and m/z range gap filler algorithm with an m/z tolerance of 0.009 m/z or 11.0 ppm, (viii) Identification of lipids using a custom database search with an m/z tolerance of 0.008 m/z or 8.0 ppm and a RT tolerance of 0.25 min. Identification of lipids was based on an in-house librarybased on LC-MS/MS data on retention time and mass spectra. The identification was done with a custom data base, with identification levels 1 and 2, *i.e.*, based on authentic standard compounds (level 1) or based on MS/MS identification (level 2).

Quantification of lipids was performed using a 7-point internal calibration curve (0.1-5 µg/mL) using the following lipid-class specific authentic standards: using 1-hexadecyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine (PC(16:0e/18:1(9Z))), 1-(1Z-octadecenyl)-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine (PC(18:0p/18:1(9Z))), 1-stearoyl-2-hydroxy-sn-glycero-3-phosphocholine (LPC(18:0)), 1-oleoyl-2-hydroxy-sn-glycero-3-phosphocholine (LPC(18:1)), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (PE(16:0/18:1)), 1-(1Z-octadecenyl)-2-docosaheptaenoyl-sn-glycero-3-phosphocholine (PC(18:0p/22:6)) and 1-stearoyl-2-linoleoyl-sn-glycerol (DG(18:0/18:2)), 1-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (LPE(18:1)), N-(9Z-octadecenoyl)-sphinganine (Cer(d18:0/18:1(9Z))), 1-hexadecyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (PE(16:0/18:1)) from Avanti Polar Lipids, 1-Palmitoyl-2-Hydroxy-sn-Glycero-3-Phosphatidylcholine (LPC(16:0)), 1,2,3-trihexadecanoglycerol (TG(16:0/16:0/16:0)), 1,2,3-trioctadecanoylglycerol (TG(18:0/18:0/18:0)) and 3β-hydroxy-5-cholestene-3-stearate (ChoE(18:0)), 3β-Hydroxy-5-cholestene-3-linoleate (ChoE(18:2)) from Larodan, were prepared to the following concentration levels: 100, 500, 1000, 1500, 2000 and 2500 ng/mL (in CHCl₃:MeOH, 2:1, v/v) including 1250 ng/mL of each internal standard.

Analysis of polar metabolites

40 µl of serum sample was mixed with 90 µl of cold MeOH/H₂O (1:1, v/v) containing the internal standard mixture (Valine-d₈, Glutamic acid-d₅, Succinic acid-d₄, Heptadecanoic acid, Lactic acid-d₃, Citric acid-d₄, 3-Hydroxybutyric acid-d₄, Arginine-d₇, Tryptophan-d₅, Glutamine-d₅, each at c= 1 µg/mL-1 and 1-D₄-CA, 1-D₄-CDCA, 1-D₄-CDCA, 1-D₄-GCA, 1-D₄-GCDCA, 1-D₄-GLCA, 1-D₄-GUDCA, 1-D₄-LCA, 1-D₄-TCA, 1-D₄-UDCA, each at 0.2 1 µg/mL-1) for protein precipitation. The tube was vortexed and ultrasonicated for 3 min, followed by centrifugation (10000 rpm, 5 min). After centrifuging, 90 µl of the upper layer of the solution was transferred to the LC vial and evaporated under the nitrogen gas to the dryness. After drying, the sample was reconstituted into 60 µl of MeOH: H₂O (70:30).

Analyses were performed on an Agilent 1290 Infinity LC system coupled with 6545 QTOFMS interfaced with a dual jet stream electrospray (dual ESI) ion source (Agilent Technologies; Santa Clara, CA, USA) was used for the analysis. Aliquots of 10 μ L of samples were injected into the Acquity UPLC BEH C18 2.1 mm $\times$ 100 mm, 1.7- μ m column (Waters Corporation, Wexford, Ireland), fitted with a C18 precolumn (Waters Corporation, Wexford, Ireland). The mobile phases consisted of (A) 2 mM NH₄Ac in H₂O: MeOH (7:3) and (B) 2 mM NH₄Ac in MeOH. The flow rate was set at 0.4 mLmin⁻¹ with the elution gradient as follows: 0-1.5 min, mobile phase B was increased from 5% to 30%; 1.5-4.5 min, mobile phase B increased to 70%; 4.5-7.5 min, mobile phase B increased to 100% and held for 5.5 min. A post-time of 5 min was used to regain the initial conditions for the next analysis. The total run time per sample was 20 min. The dual ESI ionization source was settings were as follows: capillary voltage was 4.5 kV, nozzle voltage 1500 V, N₂ pressure in the nebulized was 21 psi and the N₂ flow rate and temperature as sheath gas was 11 Lmin⁻¹ and 379 °C, respectively. In order to obtain accurate mass spectra in MS scan, the m/z range was set to 100-1700 in negative ion mode. MassHunter B.06.01 software (Agilent Technologies; Santa Clara, CA, USA) was used for all data acquisition.

MS data processing was performed using same parameters as in lipidomic analysis.

Quantitation was done using 6-point calibration (PFOA c= 3.75-120 ng/mL, bile acids c= 20-640 ng/mL, polar metabolites c=0.1 to 80 μ g/mL). Quantification of other bile acids was done using the following compounds: chenodeoxycholic acid (CDCA), cholic acid (CA), deoxycholic acid (DCA), glycochenodeoxycholic acid (GCDCA), glycocholic acid (GCA), glycodehydrocholic acid (GDCA), glycodeoxycholic acid (GDCA), glycohyocholic acid (GHCA), glycohyodeoxycholic acid (GHDCA), glycolitocholic acid (GLCA), glycoursodeoxycholic acid (GUDCA), hyocholic acid (HCA), hyodeoxycholic acid (HDCA), lithocholic acid (LCA), alpha-muricholic acid (α MCA), tauro-alpha-muricholic acid (T- α -MCA), tauro-beta-muricholic acid (T- β -MCA), taurochenodeoxycholic acid (TCDCA), taurocholic acid (TCA), taurodehydrocholic acid (THCA), taurodeoxycholic acid (TDCA), taurohyodeoxycholic acid (THDCA),

taurochenodeoxycholic acid (TLCA), tauro-omega-muricholic acid (T ω MCA) and tauroursodeoxycholic acid (TDCA) and polar metabolites was done using alanine, citric acid, fumaric acid, glutamic acid, glycine, lactic acid, malic acid, 2-hydroxybutyric acid, 3-hydroxybutyric acid, linoleic acid, oleic acid, palmitic acid, stearic acid, cholesterol, fructose, glutamine, indole-3-propionic acid, isoleucine, leucine, proline, succinic acid, valine, asparagine, aspartic acid, arachidonic acid, glycerol-3-phosphate, lysine, methionine, ornithine, phenylalanine, serine and threonine.

QC/QA

Quality control was accomplished both for lipidomics, polar metabolites and PFAS analysis by including blanks, pure standard samples, extracted standard samples, pooled quality control samples and standard reference plasma samples (NIST SRM 1950). The pooled sample were prepared by taking an aliquot (10 μ l) of each extract, separately for lipidomic and polar metabolite methods, then pooling them, and aliquoting the pool into separate vials. In lipidomic and metabolomic analyses, lipids that had >30% RSD in the pooled QC samples (an equal aliquot of each sample pooled together) or that were present at high concentrations in the extracted blank samples (ratio between samples to blanks < 5) were excluded from the data analyses.

Statistical analysis

Data pre-processing and clustering

In this study, all data analyses were conducted using the R statistical programming language (version 4.1.2) (<https://www.r-project.org/>). The exposure datasets were pre-processed by log2 transformation and scaling to zero mean and unit variance (auto-scaled). For contaminant exposure analyses, individual contaminant and cluster-level analyses were performed. To cluster the contaminant data, we utilized the ‘*mclust*’ R package (version 5.4.10) for model-based clustering, selecting the model type and the number of clusters based on the highest Bayesian Information Criterion (BIC). To better understand the impact of exposure, we also incorporated lipidomics and

225 metabolomics data from our previous study (Hyotylainen et al. 2023), which included eight lipid
226 clusters (LCs) and twelve polar metabolite clusters (PCs), along with their individual features.

227 *Demographic data and covariates*

228 In terms of demographic data and covariates, the median age at the time of diagnosis for subjects
229 who later developed autoimmune diseases was 15 years. We obtained information on birthweight,
230 maternal age, gestational age, and BMI from the questionnaire. Additionally, we utilized
231 birthweight and gestational age to calculate birthweight for gestational age (BWGA) Z-score,
232 utilizing internationally validated infant growth charts developed by Fenton (Chou et al. 2020;
233 Fenton and Kim 2013).

234 *Correlation and partial correlation analysis*

235 Pairwise Spearman's correlation between contaminants, lipid clusters (LCs), Polar metabolite
236 clusters (PCs) and demographic variables (Z-score, Maternal age, BMI) was calculated and
237 visualized using ‘*corrplot*’ R package (version 0.92). Two correlation plots were generated
238 separately for control and cases. The correlation between variables visualised in the form of a
239 matrix plot refers to positive and negative correlations and the strength of the association is referred
240 to by the size of the dot or filled circles.

241 The Debiased Sparse Partial Correlation algorithm (DSPC) (Basu et al. 2017) was used to estimate
242 partial correlation networks and visualized in the form of a chord diagram using ‘*circlize*’, R
243 package (version 0.4.15) with edge ranges between ± 0.14 to 1.0 and showing only correlations
244 across contaminants, LCs, PCs and demographic variables.

245 *Univariate statistical analysis*

246 To understand the impact of contaminant exposure levels on cord serum metabolome, the subjects
247 were assigned to four quartiles based on the exposure levels. A two-way analysis of variance
248 (ANOVA) test was performed followed by post-hoc Tukey’s test by using quartiles (Q1 to Q4)

and subjects (cases and control) as factor variables. ANOVA test helps to identify any significant changes in the lipid or metabolite clusters and post-hoc Tukey's test helps to identify the specific quartiles between which significant changes are observed.

Regression and classification analysis

Predictive logistic ridge regression (LRR) was performed to investigate the impact of individual contaminants on the stratification of autoimmune cases and controls. We have adapted the L2 regularization strategy to avoid multicollinearity among highly correlated predictors. Regularized regression modelling was performed using the '*glmnet*' package in R (version 4.1-4). The hyper-parameter λ_{minimum} was determined by 10-fold cross-validation using the '*cv.glmnet*' function from '*glmnet*'. The models were adjusted for Z-score, Maternal age and BMI. The accuracy of prediction was determined by AUCs, where the mean AUC of the model was estimated by bootstrapping, by resampling the exposure dataset into training (80%) and testing (20%) 10,000 times. All LRR models with a threshold of $\text{AUC} > 0.60$ were considered. Downsampling was performed to address the class imbalance problem (cases, $n=62$, controls, $n > 62$). The '*caret*' package (version 4.1.3) was used for the partition of data and the best models (based on mean AUCs) were assessed using Receiver Operating Characteristic (ROC) curves using the '*ROCR*' package. Additionally, we have performed a stepwise recursive feature elimination scheme to identify the minimum number of predictors that are needed to maximize the outcome.

To investigate the effect of contaminant exposure on the cord blood metabolome, we employed linear regression with L2 regularization (LR), using individual contaminant concentrations as predictors and the concentrations of significantly altered cord blood lipid or polar metabolites (and their cluster) as the response variable. The hyper-parameter λ_{minimum} , which corresponds to the minimum cross-validation error, was selected through 10-fold cross-validation. We partitioned the data and performed resampling (10,000 iterations) as described earlier. The mean R square was used to estimate the accuracy of prediction and the significant impact of contaminant exposure on the cord blood metabolome.

Additionally, we determined the ranks of the predictors using LR and LRR modelling. For the LRR models, the ranks of the predictors were estimated based on the unit absolute differences in the odds ratio, while for the LR models, the ranks were based on the ridge coefficients normalized with the maximum value.

Pathway analysis

Pathway enrichment analysis comparing cases versus controls for Deoxynivalenol (DON) impact polar metabolites was performed using the MetaboAnalyst 5.0 web platform with the Functional Analysis (MS Peaks) module (Pang et al. 2022). The input data for the pathway analysis consisted of complete high-resolution LC-MS spectral peak data obtained in negative ionization mode with a mass tolerance of 10 ppm. Linear regression analysis was performed to estimate the association between DON and polar metabolites while adjusting for Z-score, Maternal age, and BMI. The whole input peak list with FDR-corrected p-values and T-score was used for the pathway analysis. Overrepresented pathways were estimated against the background human scale metabolic model MNF (from MetaboAnalyst Mummichog package) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways for Homo sapiens to determine the relative significance of the identified pathways (Li et al. 2020). The MetaboAnalyst 5.0 metabolomics pathway analysis (MetPA) tool (Xia and Wishart 2010) was used to calculate the Pathway Impact Scores (Chong et al. 2018; Pang et al. 2022).

Results

Metabolomic analysis of the cord blood

Fig. 1 summarizes the integration of exposomics and metabolomics workflows in the ABIS cohort. Cord serum samples were analyzed for a total of 545 lipids and 3417 polar metabolites, which were further grouped into 8 lipid clusters and 12 polar metabolite clusters, respectively. We previously found significant associations between the metabolite clusters and demographic

variables or clinical parameters such as gestational age, maternal age, and birth weight (Hyotylainen et al. 2023). To account for these associations, we used the Z-score as calculated from birth weight, gestational age, and maternal BMI as covariates in our analysis.

Levels of contaminants in the cord blood

A total of 20 contaminants, including several PFAS compounds, were detected in cord blood samples from both control and case groups (**Table S1**). Differences ($p < 0.05$) in concentration levels between control and case groups were observed for Perfluorooctanoic acid Branched 2, Environmental Contaminant 1, Perfluorooctanoic acid Linear 1, Perfluorooctanoic acid Linear 2 and Methylparaben (**Fig. 2**). At the individual disease level, Environmental Contaminant 1, Perfluorooctanoic acid Linear 2 and Perfluorooctanoic acid Branched 2 showed differences ($p < 0.05$) in concentration levels between control and individual disease groups (**Fig. S1**). The contaminants were reduced to four clusters (CC1-CC4) consisting of eight contaminants, including Bisphenol S, Deoxynivalenol, Monobutyl phthalate, and α -Zearalanol in CC1; Ethylparaben, Methylparaben, and Propylparaben in CC2; Perfluorohexanesulfonic acid (PFHxS) and Perfluorohexanesulfonic acid Branched (PFHxSBr) in CC3; and seven PFAS and their fragments as part of CC4 (**Table S1**).

Exposure level of contaminants as a predictor for immune-mediated diseases

We employed predictive logistic ridge regression (LRR) models to stratify controls and cases based on their contaminant concentrations. The models were fitted using all predictors or by using the stepwise recursive feature elimination (RFE) method. The mean area under the curve (AUC) values for the models were 0.65 (95% CI 0.63-0.67) when using all predictors and 0.67 (95% CI 0.66-0.68) when using the stepwise RFE method (**Fig. S2**). Our results showed that the contaminant concentration levels have a modest potential to differentiate controls from autoimmune diseases, as indicated by the mean AUC values (**Fig. S2**). The ranks of individual

contaminants (predictors) for separating controls and cases were estimated based on the unit absolute difference in odds ratios (**Fig. S2A**).

Associations between contaminants and cord serum metabolic profiles

We found significant associations between contaminants and cord serum metabolic profiles (**Fig. 3**). Specifically, more associations were observed between PFAS exposures and metabolic profiles in cases than in controls. Maternal age was positively associated with metabolite cluster PC1 in cases but not in controls (**Fig. 3**). We also performed partial correlation network analysis to identify non-spurious associations and **Fig. 4** shows the marked associations between contaminants and cord serum metabolic profiles along with demographic variables. In the case group (**Fig. 4B**), the covariates Z-score, maternal age, and BMI showed a stronger association with exposure and cord serum metabolic profiles compared to the control group (**Fig. 4A**). The mycotoxins including deoxynivalenol were found to be associated with PC2 (phosphatidylcholines) and PC10 (unknowns), while a-zearalanol was associated with PC1 (lysophosphatidylcholines, sphingomyelins, and ceramides) (**Fig. 4**).

Impact of contaminant exposure on cord serum metabolites associated with immune-mediated diseases

The samples were stratified into quartiles based on their level of exposure to contaminants, and the impact of exposure on metabolite levels was assessed at both individual contaminant levels and cluster levels (CC1-CC4) (**Tables S2-S5**). The polar metabolite clusters displayed more significant mean differences between the highest (Q4) and lowest (Q1) quartiles, as shown in **Table S4-S5**. In CC1, significant mean differences between Q4 and Q1 were observed for LC3, LC4, and LC7 at the lipid cluster level (**Table S3**). In CC3, which includes perfluorohexanesulfonic acid (PFHxS) and branched (PFHxSBr), significant mean differences between the highest and lowest quartiles were observed for LC5 and LC6 (**Table S3** and **Fig. 5H**).

Linear ridge regression (LR) was performed to determine the quantitative effect of contaminant concentration levels on cord serum metabolic profiles. The results showed that polar metabolites in cord serum were more highly impacted by contaminant exposure than lipid levels. Specifically, six polar metabolite clusters, PC2 ($R^2 = 0.72$), PC6 ($R^2 = 0.53$), PC4 ($R^2 = 0.52$), PC1 ($R^2 = 0.48$), PC10 ($R^2 = 0.48$), and PC11 ($R^2 = 0.32$), showed significant associations with exposure levels (**Fig. 5** and **Fig. S3**). At the individual metabolite level, amino acids such as tryptophan (**Fig. 5C**), Serine of PC2, and 3-Chlorothiopheno [2,3-b]thiophene-2-carbonyl chloride of PC11 showed a significant impact (**Fig. 5F**). According to the ranks of the predictors (contaminants), deoxynivalenol (DON) and Bisphenol S were the top linear predictors of cord serum metabolites and clusters PC2 and PC11 (**Fig. 5A-F**).

Although the contaminants from clusters CC1 and CC3 showed a significant association between quartiles (Q4 vs. Q1) and lipid cluster levels LC3, LC4, LC5, LC6, and LC7, their strength of association based on LR models was comparatively weaker (**Fig. 5G-I** and **Fig. S3**). For example, the lipid cluster LC6, which mainly comprises triglycerides containing monounsaturated fatty acid (MUFA) and polyunsaturated fatty acids (PUFA), showed a weaker association ($R^2 = 0.04$) with contaminant exposures (**Fig. 5G-I**).

Pathway analysis of deoxynivalenol exposure

Metabolic pathway enrichment analysis was performed to evaluate the impact of DON on polar metabolites in both control and case groups separately. DON was found to be the top predictor that impacted polar metabolite clusters PC2, PC4, PC10, and PC11, as shown in **Fig. 5** and **Fig. S3**. Both Mummichog and GeneSet Enrichment Analysis (GSEA) algorithms were utilized using MetaboAnalyst 5.0 (Li et al. 2020; Pang et al. 2022). Based on the pathways identified by the impact of DON exposure, both control and case groups showed common and specific metabolic pathways, as presented in **Tables S6-S9**.

The MFN pathway map revealed that DON exposure was associated with ‘Tyrosine and Tryptophan metabolism’ in the control group but not in cases. Also ‘Glutathione Metabolism’, ‘Alanine and Aspartate Metabolism’, and ‘Glycerophospholipid metabolism’ were found to be associated with exposure to DON in cases, but not in controls (**Fig. 6A** and **6C**; **Tables S6** and **S8**). Similarly, based on the KEGG pathway maps, ‘Aminoacyl-tRNA biosynthesis’ and ‘Glycine, serine, and threonine metabolism’ were common among control and case groups, while several other metabolic pathways were specific to each group (**Fig. 6B** and **6D**, **Tables S7** and **S9**). In summary, the pathway enrichment analysis provided insights into the metabolic pathways affected by DON exposure in both control and case groups. The results highlight the differences in the impacted pathways between the two groups based on the exposure to DON.

Discussion

We performed integrated exposomics and metabolomics to detect the levels of exposure to contaminants and metabolite levels in cord serum. This comprehensive approach allowed us to assess the combined impact of environmental exposures and metabolic profiles on autoimmune diseases in the ABIS cohort. In our previous study we found similarities in metabolic profiles across different autoimmune diseases at birth (Hyotylainen et al. 2023). In order to avoid class imbalance problems, here we pooled all individual diseases together. We detected 20 contaminants, encompassing several PFAS compounds, Bisphenol S, and mycotoxins like Deoxynivalenol (DON), in cord blood samples from both control and case groups. Previous studies, including our own, have reported detectable levels of PFAS compounds (McGlinchey et al. 2020; Sinisalu et al. 2020), Bisphenol S exposure (Liu et al. 2017), and the presence of mycotoxins, including Deoxynivalenol (DON), in cord blood samples (Nielsen et al. 2011). These findings provide a backdrop for our investigation into the associations between these contaminants and autoimmune diseases in the ABIS cohort. We were able to demonstrate significant differences in the exposure levels of certain contaminants, such as Perfluorooctanoic acid Branched 2, Environmental Contaminant 1, Perfluorooctanoic acid Linear 1, Perfluorooctanoic acid Linear 2,

and Methylparaben, in cord blood between the control and case groups. However, it is important to note that while these differences were statistically significant, the effect sizes were relatively modest. This suggests that while contaminants do play a role in distinguishing between controls and autoimmune diseases, they are unlikely to be the sole risk factors. Various factors including genetics, environmental triggers, and lifestyle factors, and their mutual interactions, contribute to the development of autoimmune diseases (Ellis et al. 2014; Oresic et al. 2013; Oresic et al. 2008; Rewers and Ludvigsson 2016; Sen et al. 2019; Sen et al. 2020; Sinisalu et al. 2020; Vermeulen et al. 2020; Virolainen et al. 2023).

Our study revealed differences in exposure and metabolite profiles between individuals who later developed autoimmune diseases and controls, particularly in relation to Z-score, mothers' age, and BMI. This suggests that there may be differences in maternal factors between the two groups even at birth. We also observed that high levels of exposure to environmental contaminants were associated with changes in amino acid and free fatty acid profiles in the cord blood metabolome. Although we previously found a significant impact on lipid profiles, particularly triacylglycerols, the strength of association is weaker compared to the effect on polar metabolites (Hyotylainen et al. 2023). Among the 20 contaminants measured in our study, DON, Bisphenol S, and some branched PFAS compounds are the primary predictors of changes in cord serum metabolic profiles. While the associations between PFAS exposure and their marked effect on metabolism leading to autoimmune diseases have been well documented in previous studies (Ehrlich et al. 2023; McGlinchey et al. 2020; Rudzanova et al. 2023; Sinisalu et al. 2020), the exposure to DON and BPS and their impact on autoimmune diseases is less studied.

While our study detected Bisphenol S (BPS) and not Bisphenol A (BPA), it's noteworthy that BPA, a common chemical found in plastics, has been associated with alterations in amino acid metabolism (Wang et al. 2018). BPA has been linked to changes in phenylalanine, tryptophan, tyrosine, lysine, and arginine metabolism, with a particular impact on female infants (Khan et al. 2017). In the case of BPS, it was shown to have sex- and diet-dependent effects on the development

of type 1 diabetes (T1D) in non-obese diabetic (NOD) mice. Female mice exposed to BPS on a soy-based diet exhibited delayed T1D development, while males showed increased insulin resistance (Xu et al. 2019). These findings suggest that both BPA and BPS can influence metabolism and immune responses, potentially contributing to autoimmune diseases like T1D, although there is less evidence regarding the effect of BPS in humans.

Deoxynivalenol (DON) exposure in pregnant women has been reported in various studies. In the UK, pregnant women from diverse backgrounds showed detectable urinary DON levels, with South Asian women having higher exposure, primarily from bread consumption (Hepworth et al. 2012). Similarly, in Norway, DON, a common mycotoxin in cereals, was found in various cereal-based foods, potentially affecting the immune system, particularly in infants and young children (Sundheim et al. 2017). In pregnant Egyptian women, DON co-occurred with other mycotoxins, raising concerns about maternal and fetal health (Piekkola et al. 2012).

These findings emphasize the importance of assessing DON exposure in pregnant women and its potential health implications. DON exposure, prevalent in grains, adversely affects the immune system in both humans and animals and has been linked to alterations in gut microbiota (Liao et al. 2018). This immunotoxicity induced by DON involves mechanisms such as MAPK activation, ER stress, and mitochondrial signaling pathways (Liao et al. 2018).

To delve deeper into the potential mechanisms underlying these associations, we conducted pathway analysis of DON exposure on polar metabolites within both control and case groups. This analysis revealed that DON had distinct impacts on metabolic pathways in these groups. In the control group, DON exposure was associated with alterations in 'Tyrosine and Tryptophan metabolism,' indicating potential effects on amino acid pathways. Conversely, the case group showed associations between DON exposure and 'Glutathione Metabolism,' 'Alanine and Aspartate Metabolism,' and 'Glycerophospholipid metabolism,' suggesting disruptions in antioxidant defense systems and lipid metabolism. These findings align with previous research indicating that DON can induce oxidative stress by reducing antioxidant enzyme activity and

enhancing lipid peroxidation (Mishra et al. 2014). The marked association between DON and phosphatidylcholines in our study suggests a potential link between mycotoxin exposure and alterations in lipid metabolism, particularly in the context of phosphatidylcholines. This finding is noteworthy, as specific phosphatidylcholines were previously identified as persistently down-regulated in children who later progressed to islet autoimmunity (Johnson et al. 2019) and clinical type 1 diabetes (T1D) (Oresic et al. 2008). Thus, the oxidative stress response and its impact on lipid metabolism, triggered by DON exposure, may play a pivotal role in the pathogenesis of autoimmune diseases, warranting further investigation.

These differential effects of DON exposure on metabolic pathways between control and case groups highlight the intricate relationship between environmental exposures, metabolism, and immune dysregulation in the context of autoimmune diseases. While our study contributes to our understanding of the metabolic consequences of DON exposure, it's essential to consider these findings within the broader context of various factors, including genetics, environmental triggers, and lifestyle factors, which collectively contribute to the development of autoimmune diseases. Understanding these effects is crucial when assessing DON exposure during pregnancy and its potential health consequences. In this study, the median age of diagnosis of autoimmune diseases was higher compared to previous studies in genetically high-risk cohorts (Oresic et al. 2013; Oresic et al. 2008; Sen et al. 2019). Despite some common metabolic patterns (Hyotylainen et al. 2023), there were differences and limitations to consider. One important limitation of our study was the small sample size within each disease group, which restricted our analysis. Another limitation of our study was the lack of maternal exposure and longitudinal exposure data at different time points between birth and the onset of autoimmune diseases, which could explain their age-dependent progression.

Our previous studies in T1D (McGlinchey et al. 2020) and CD (Sinisalu et al. 2020) cohorts have mainly focus on the associations of PFAS exposure with the disease risk. Here we detected the levels of other contaminants such as Bisphenol S and some mycotoxins including DON and a-

Zearalanol, which potentially show the differences in exposures. Mycotoxins are common contaminants of cereals and grains, and exposure to them is also associated with autoimmune disorders (Gayathri et al. 2018; Kraft et al. 2021; Liao et al. 2018; Rotter et al. 1996). This emphasizes the need for caution and control over mycotoxin exposure, particularly during pregnancy and critical developmental stages.

Altogether, our results show that high prenatal exposure to environmental contaminants associated with altered cord serum metabolite levels and may result in the progression of autoimmune diseases in the ABIS cohort. Other factors such as Z-score, maternal age and BMI are associated with contaminant exposure levels. Mechanistic studies are required to elucidate pathways of disease progression upon exposure.

Author contributions

Bagavathy Shanmugam Karthikeyan: Formal analysis, Software, Visualization, Writing - Original Draft; Tuulia Hyötyläinen: Conceptualization, methodology, formal analysis, investigation, writing – original draft, supervision, project administration, funding acquisition; Tannaz Ghaffarzadegan: Writing – review and editing, methodology; Eric W. Triplett: Conceptualization, writing – review and editing; Matej Orešič: Conceptualization, writing – original draft, formal analysis, supervision; Johnny Ludvigsson: Conceptualization, writing – review and editing, funding acquisition, design and management of the ABIS cohort study.

Acknowledgements

BSK thanks Partho Sen for his guidance in Methods and Alex Dickens for his insightful discussions. The authors thank Dirk Repsilber for his support in using the UCS-1 server from Örebro University for computations. This work was supported by the Swedish Research Council [grant number 2020-03674; to TH], Formas [grant number 2019-00869; to TH], and by the “Inflammation in human early life: targeting impacts on life-course health” (INITIALISE)

consortium funded by the Horizon Europe Program of the European Union under Grant Agreement 101094099 (to T.H., E.W.T., M.O., and J.L.). The ABIS cohort study (JL) was supported by Barndiabetesfonden (Swedish Child Diabetes Foundation), the Swedish Council for Working Life and Social Research [grant numbers FAS2004-1775 and FAS2004–1775], Swedish Research Council [Grant/Award Numbers: K2005-72 × -11242-11A and K2008-69 × -20826-01-4, K2008-69 × -20826-01-4], Östgöta Brandstodsbolag, Medical Research Council of Southeast Sweden (FORSS), JDRF Wallenberg Foundation [Grant/Award Number: K 98-99D-12813-01A], Joanna Coccozza Foundation and ALF-and LfoU grants from Region Östergötland and Linköping University, Sweden.

Competing interests

The authors have no competing interests to declare.

Data accessibility

Data are available upon reasonable request after ethical approval and an appropriate institutional collaboration agreement. These data are not available to access in a repository owing to concern that the identity of patients might be revealed inadvertently.

References

- Basu, S.; Duren, W.; Evans, C.R.; Burant, C.F.; Michailidis, G.; Karnovsky, A. Sparse network modeling and metscape-based visualization methods for the analysis of large-scale metabolomics data. *Bioinformatics* 2017;33:1545-1553
- Belteky, M.; Milletich, P.L.; Ahrens, A.P.; Triplett, E.W.; Ludvigsson, J. Infant gut microbiome composition correlated with type 1 diabetes acquisition in the general population: the ABIS study. *Diabetologia* 2023;66:1116-1128
- Berhan, Y.; Waernbaum, I.; Lind, T.; Mollsten, A.; Dahlquist, G.; Swedish Childhood Diabetes Study, G. Thirty years of prospective nationwide incidence of childhood type 1 diabetes: the accelerating increase by time tends to level off in Sweden. *Diabetes* 2011;60:577-581
- Buhimschi, I.A.; Buhimschi, C.S. Proteomics/diagnosis of chorioamnionitis and of relationships with the fetal exposome. *Semin Fetal Neonatal Med* 2012;17:36-45
- Carstensen, B.; Ronn, P.F.; Jorgensen, M.E. Prevalence, incidence and mortality of type 1 and type 2 diabetes in Denmark 1996-2016. *BMJ Open Diabetes Res Care* 2020;8

529 Chew, N.W.S.; Ng, C.H.; Tan, D.J.H.; Kong, G.; Lin, C.; Chin, Y.H.; Lim, W.H.; Huang, D.Q.;
530 Quek, J.; Fu, C.E.; Xiao, J.; Syn, N.; Foo, R.; Khoo, C.M.; Wang, J.W.; Dimitriadis,
531 G.K.; Young, D.Y.; Siddiqui, M.S.; Lam, C.S.P.; Wang, Y.; Figtree, G.A.; Chan, M.Y.;
532 Cummings, D.E.; Nouredin, M.; Wong, V.W.; Ma, R.C.W.; Mantzoros, C.S.; Sanyal,
533 A.; Muthiah, M.D. The global burden of metabolic disease: Data from 2000 to 2019. *Cell*
534 *Metab* 2023;35:414-428 e413

535 Chong, J.; Soufan, O.; Li, C.; Caraus, I.; Li, S.; Bourque, G.; Wishart, D.S.; Xia, J.
536 *MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis.*
537 *Nucleic Acids Res* 2018;46:W486-W494

538 Chou, J.H.; Roumiantsev, S.; Singh, R. *PediTools Electronic Growth Chart Calculators:*
539 *Applications in Clinical Care, Research, and Quality Improvement. J Med Internet Res*
540 2020;22:e16204

541 Cui, Y.; Balshaw, D.M.; Kwok, R.K.; Thompson, C.L.; Collman, G.W.; Birnbaum, L.S. The
542 *Exposome: Embracing the Complexity for Discovery in Environmental Health. Environ*
543 *Health Perspect* 2016;124:A137-140

544 Diseases, G.B.D.; Injuries, C. Global burden of 369 diseases and injuries in 204 countries and
545 territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study
546 2019. *Lancet* 2020;396:1204-1222

547 Eaton, W.W.; Rose, N.R.; Kalaydjian, A.; Pedersen, M.G.; Mortensen, P.B. Epidemiology of
548 autoimmune diseases in Denmark. *J Autoimmun* 2007;29:1-9

549 Ehrlich, V.; Bil, W.; Vandebriel, R.; Granum, B.; Luijten, M.; Lindeman, B.; Grandjean, P.;
550 Kaiser, A.M.; Hauzenberger, I.; Hartmann, C.; Gundacker, C.; Uhl, M. Consideration of
551 pathways for immunotoxicity of per- and polyfluoroalkyl substances (PFAS). *Environ*
552 *Health* 2023;22:19

553 Ellis, J.A.; Kemp, A.S.; Ponsonby, A.L. Gene-environment interaction in autoimmune disease.
554 *Expert Rev Mol Med* 2014;16:e4

555 Fenton, T.R.; Kim, J.H. A systematic review and meta-analysis to revise the Fenton growth chart
556 for preterm infants. *BMC Pediatr* 2013;13:59

557 Filimoniuk, A.; Daniluk, U.; Samczuk, P.; Wasilewska, N.; Jakimiec, P.; Kucharska, M.;
558 Lebensztejn, D.M.; Ciborowski, M. Metabolomic profiling in children with inflammatory
559 bowel disease. *Adv Med Sci* 2020;65:65-70

560 Gayathri, L.; Karthikeyan, B.S.; Rajalakshmi, M.; Dhanasekaran, D.; Li, A.P.; Akbarsha, M.A.
561 *Metabolism-dependent cytotoxicity of citrinin and ochratoxin A alone and in*
562 *combination as assessed adopting integrated discrete multiple organ co-culture (IdMOC).*
563 *Toxicol In Vitro* 2018;46:166-177

564 Harjutsalo, V.; Sund, R.; Knip, M.; Groop, P.H. Incidence of type 1 diabetes in Finland. *JAMA*
565 2013;310:427-428

566 Hepworth, S.J.; Hardie, L.J.; Fraser, L.K.; Burley, V.J.; Mijal, R.S.; Wild, C.P.; Azad, R.;
567 McKinney, P.A.; Turner, P.C. Deoxynivalenol exposure assessment in a cohort of
568 pregnant women from Bradford, UK. *Food Addit Contam Part A Chem Anal Control*
569 *Expo Risk Assess* 2012;29:269-276

570 Hyotylainen, T.; Karthikeyan, B.S.; Ghaffar zadegan, T.; Triplett, E.W.; Oresic, M.; Ludvigsson,
571 J. Cord serum metabolic signatures of future progression to immune-mediated diseases.
572 iScience 2023;26:106268

573 Ilonen, J.; Kiviniemi, M.; Lempainen, J.; Simell, O.; Toppari, J.; Veijola, R.; Knip, M.; Finnish
574 Pediatric Diabetes, R. Genetic susceptibility to type 1 diabetes in childhood - estimation
575 of HLA class II associated disease risk and class II effect in various phases of islet
576 autoimmunity. *Pediatr Diabetes* 2016;17 Suppl 22:8-16

577 Johnson, R.K.; Tamura, R.; Frank, N.; Uusitalo, U.; Yang, J.; Niinisto, S.; Andren Aronsson, C.;
578 Ziegler, A.G.; Hagopian, W.; Rewers, M.; Toppari, J.; Akolkar, B.; Krischer, J.;
579 Virtanen, S.M.; Norris, J.M.; Group, T.S. Maternal food consumption during late
580 pregnancy and offspring risk of islet autoimmunity and type 1 diabetes. *Diabetologia*
581 2021;64:1604-1612

582 Johnson, R.K.; Vanderlinden, L.; DeFelice, B.C.; Kechris, K.; Uusitalo, U.; Fiehn, O.; Sontag,
583 M.; Crume, T.; Beyerlein, A.; Lernmark, A.; Toppari, J.; Ziegler, A.G.; She, J.X.;
584 Hagopian, W.; Rewers, M.; Akolkar, B.; Krischer, J.; Virtanen, S.M.; Norris, J.M.;
585 Group, T.S. Metabolite-related dietary patterns and the development of islet
586 autoimmunity. *Sci Rep* 2019;9:14819

587 Karthikeyan, B.S.; Ravichandran, J.; Aparna, S.R.; Samal, A. ExHuMId: A curated resource and
588 analysis of Exposome of Human Milk across India. *Chemosphere* 2021;271:129583

589 Katsarou, A.; Gudbjornsdottir, S.; Rawshani, A.; Dabelea, D.; Bonifacio, E.; Anderson, B.J.;
590 Jacobsen, L.M.; Schatz, D.A.; Lernmark, A. Type 1 diabetes mellitus. *Nat Rev Dis*
591 *Primers* 2017;3:17016

592 Khan, A.; Park, H.; Lee, H.A.; Park, B.; Gwak, H.S.; Lee, H.R.; Jee, S.H.; Park, Y.H. Elevated
593 Metabolites of Steroidogenesis and Amino Acid Metabolism in Preadolescent Female
594 Children With High Urinary Bisphenol A Levels: A High-Resolution Metabolomics
595 Study. *Toxicol Sci* 2017;160:371-385

596 Khan, M.F.; Wang, H. Environmental Exposures and Autoimmune Diseases: Contribution of
597 Gut Microbiome. *Front Immunol* 2019;10:3094

598 Kindgren, E.; Ahrens, A.P.; Triplett, E.W.; Ludvigsson, J. Infant gut microbiota and
599 environment associate with juvenile idiopathic arthritis many years prior to disease onset,
600 especially in genetically vulnerable children. *EBioMedicine* 2023;93:104654

601 Kostic, A.D.; Gevers, D.; Siljander, H.; Vatanen, T.; Hyotylainen, T.; Hamalainen, A.M.; Peet,
602 A.; Tillmann, V.; Poho, P.; Mattila, I.; Lahdesmaki, H.; Franzosa, E.A.; Vaarala, O.; de
603 Goffau, M.; Harmsen, H.; Ilonen, J.; Virtanen, S.M.; Clish, C.B.; Oresic, M.;
604 Huttenhower, C.; Knip, M.; Group, D.S.; Xavier, R.J. The dynamics of the human infant
605 gut microbiome in development and in progression toward type 1 diabetes. *Cell Host*
606 *Microbe* 2015;17:260-273

607 Kraft, S.; Buchenauer, L.; Polte, T. Mold, Mycotoxins and a Dysregulated Immune System: A
608 Combination of Concern? *Int J Mol Sci* 2021;22

609 Landrigan, P.J.; Goldman, L.R. Children's vulnerability to toxic chemicals: a challenge and
610 opportunity to strengthen health and environmental policy. *Health Aff (Millwood)*
611 2011;30:842-850

Landrigan, P.J.; Sly, J.L.; Ruchirawat, M.; Silva, E.R.; Huo, X.; Diaz-Barriga, F.; Zar, H.J.; King, M.; Ha, E.H.; Asante, K.A.; Ahanchian, H.; Sly, P.D. Health Consequences of Environmental Exposures: Changing Global Patterns of Exposure and Disease. *Ann Glob Health* 2016;82:10-19

Li, S.; Cirillo, P.; Hu, X.; Tran, V.; Krigbaum, N.; Yu, S.; Jones, D.P.; Cohn, B. Understanding mixed environmental exposures using metabolomics via a hierarchical community network model in a cohort of California women in 1960's. *Reprod Toxicol* 2020;92:57-65

Liao, Y.; Peng, Z.; Chen, L.; Nussler, A.K.; Liu, L.; Yang, W. Deoxynivalenol, gut microbiota and immunotoxicity: A potential approach? *Food Chem Toxicol* 2018;112:342-354

Liu, J.; Li, J.; Wu, Y.; Zhao, Y.; Luo, F.; Li, S.; Yang, L.; Moez, E.K.; Dinu, I.; Martin, J.W. Bisphenol A Metabolites and Bisphenol S in Paired Maternal and Cord Serum. *Environ Sci Technol* 2017;51:2456-2463

Ludvigsson, J.; Ludvigsson, M.; Sepa, A. Screening for prediabetes in the general child population: maternal attitude to participation. *Pediatr Diabetes* 2001;2:170-174

McGlinchey, A.; Sinioja, T.; Lamichhane, S.; Sen, P.; Bodin, J.; Siljander, H.; Dickens, A.M.; Geng, D.; Carlsson, C.; Duberg, D.; Ilonen, J.; Virtanen, S.M.; Dirven, H.; Berntsen, H.F.; Zimmer, K.; Nygaard, U.C.; Oresic, M.; Knip, M.; Hyotylainen, T. Prenatal exposure to perfluoroalkyl substances modulates neonatal serum phospholipids, increasing risk of type 1 diabetes. *Environ Int* 2020;143:105935

Mishra, S.; Dwivedi, P.D.; Pandey, H.P.; Das, M. Role of oxidative stress in Deoxynivalenol induced toxicity. *Food Chem Toxicol* 2014;72:20-29

Nielsen, J.K.; Vikstrom, A.C.; Turner, P.; Knudsen, L.E. Deoxynivalenol transport across the human placental barrier. *Food Chem Toxicol* 2011;49:2046-2052

Nygren, M.; Carstensen, J.; Koch, F.; Ludvigsson, J.; Frostell, A. Experience of a serious life event increases the risk for childhood type 1 diabetes: the ABIS population-based prospective cohort study. *Diabetologia* 2015;58:1188-1197

Oresic, M.; Gopalacharyulu, P.; Mykkanen, J.; Lietzen, N.; Makinen, M.; Nygren, H.; Simell, S.; Simell, V.; Hyoty, H.; Veijola, R.; Ilonen, J.; Sysi-Aho, M.; Knip, M.; Hyotylainen, T.; Simell, O. Cord serum lipidome in prediction of islet autoimmunity and type 1 diabetes. *Diabetes* 2013;62:3268-3274

Oresic, M.; Simell, S.; Sysi-Aho, M.; Nanto-Salonen, K.; Seppanen-Laakso, T.; Parikka, V.; Katajamaa, M.; Hekkala, A.; Mattila, I.; Keskinen, P.; Yetukuri, L.; Reinikainen, A.; Lahde, J.; Suortti, T.; Hakalax, J.; Simell, T.; Hyoty, H.; Veijola, R.; Ilonen, J.; Lahesmaa, R.; Knip, M.; Simell, O. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. *J Exp Med* 2008;205:2975-2984

Pang, Z.; Zhou, G.; Ewald, J.; Chang, L.; Hacariz, O.; Basu, N.; Xia, J. Using MetaboAnalyst 5.0 for LC-HRMS spectra processing, multi-omics integration and covariate adjustment of global metabolomics data. *Nat Protoc* 2022;17:1735-1761

Patterson, C.C.; Dahlquist, G.G.; Gyurus, E.; Green, A.; Soltesz, G.; Group, E.S. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. *Lancet* 2009;373:2027-2033

654 Piekola, S.; Turner, P.C.; Abdel-Hamid, M.; Ezzat, S.; El-Daly, M.; El-Kafrawy, S.;
655 Savchenko, E.; Poussa, T.; Woo, J.C.; Mykkanen, H.; El-Nezami, H. Characterisation of
656 aflatoxin and deoxynivalenol exposure among pregnant Egyptian women. *Food Addit*
657 *Contam Part A Chem Anal Control Expo Risk Assess* 2012;29:962-971

658 Pluskal, T.; Castillo, S.; Villar-Briones, A.; Oresic, M. MZmine 2: modular framework for
659 processing, visualizing, and analyzing mass spectrometry-based molecular profile data.
660 *BMC Bioinformatics* 2010;11:395

661 Rewers, M.; Ludvigsson, J. Environmental risk factors for type 1 diabetes. *Lancet*
662 2016;387:2340-2348

663 Robinson, O.; Vrijheid, M. The Pregnancy Exposome. *Curr Environ Health Rep* 2015;2:204-213

664 Rosenblum, M.D.; Gratz, I.K.; Paw, J.S.; Abbas, A.K. Treating human autoimmunity: current
665 practice and future prospects. *Sci Transl Med* 2012;4:125sr121

666 Rotter, B.A.; Prelusky, D.B.; Pestka, J.J. Toxicology of deoxynivalenol (vomitoxin). *J Toxicol*
667 *Environ Health* 1996;48:1-34

668 Rudzanova, B.; Vlaanderen, J.; Kalina, J.; Piler, P.; Zvonar, M.; Klanova, J.; Blaha, L.;
669 Adamovsky, O. Impact of PFAS exposure on prevalence of immune-mediated diseases in
670 adults in the Czech Republic. *Environ Res* 2023;229:115969

671 Sen, P.; Carlsson, C.; Virtanen, S.M.; Simell, S.; Hyoty, H.; Ilonen, J.; Toppari, J.; Veijola, R.;
672 Hyotylainen, T.; Knip, M.; Oresic, M. Persistent Alterations in Plasma Lipid Profiles
673 Before Introduction of Gluten in the Diet Associated With Progression to Celiac Disease.
674 *Clin Transl Gastroenterol* 2019;10:1-10

675 Sen, P.; Dickens, A.M.; Lopez-Bascon, M.A.; Lindeman, T.; Kemppainen, E.; Lamichhane, S.;
676 Ronkko, T.; Ilonen, J.; Toppari, J.; Veijola, R.; Hyoty, H.; Hyotylainen, T.; Knip, M.;
677 Oresic, M. Metabolic alterations in immune cells associate with progression to type 1
678 diabetes. *Diabetologia* 2020;63:1017-1031

679 Shaffer, R.M.; Sellers, S.P.; Baker, M.G.; de Buen Kalman, R.; Frostad, J.; Suter, M.K.;
680 Anenberg, S.C.; Balbus, J.; Basu, N.; Bellinger, D.C.; Birnbaum, L.; Brauer, M.; Cohen,
681 A.; Ebi, K.L.; Fuller, R.; Grandjean, P.; Hess, J.J.; Kogevinas, M.; Kumar, P.; Landrigan,
682 P.J.; Lanphear, B.; London, S.J.; Rooney, A.A.; Stanaway, J.D.; Trasande, L.; Walker,
683 K.; Hu, H. Improving and Expanding Estimates of the Global Burden of Disease Due to
684 Environmental Health Risk Factors. *Environ Health Perspect* 2019;127:105001

685 Sinisalu, L.; Sen, P.; Salihovic, S.; Virtanen, S.M.; Hyoty, H.; Ilonen, J.; Toppari, J.; Veijola, R.;
686 Oresic, M.; Knip, M.; Hyotylainen, T. Early-life exposure to perfluorinated alkyl
687 substances modulates lipid metabolism in progression to celiac disease. *Environ Res*
688 2020;188:109864

689 Sundheim, L.; Lillegaard, I.T.; Faeste, C.K.; Brantsaeter, A.L.; Brodal, G.; Eriksen, G.S.
690 Deoxynivalenol Exposure in Norway, Risk Assessments for Different Human Age
691 Groups. *Toxins (Basel)* 2017;9

692 Tincani, A.; Dall'Ara, F.; Lazzaroni, M.G.; Reggia, R.; Andreoli, L. Pregnancy in patients with
693 autoimmune disease: A reality in 2016. *Autoimmun Rev* 2016;15:975-977

694 Vatanen, T.; Franzosa, E.A.; Schwager, R.; Tripathi, S.; Arthur, T.D.; Vehik, K.; Lernmark, A.;
695 Hagopian, W.A.; Rewers, M.J.; She, J.X.; Toppari, J.; Ziegler, A.G.; Akolkar, B.;

696 Krischer, J.P.; Stewart, C.J.; Ajami, N.J.; Petrosino, J.F.; Gevers, D.; Lahdesmaki, H.;
697 Vlamakis, H.; Huttenhower, C.; Xavier, R.J. The human gut microbiome in early-onset
698 type 1 diabetes from the TEDDY study. *Nature* 2018;562:589-594

699 Vermeulen, R.; Schymanski, E.L.; Barabasi, A.L.; Miller, G.W. The exposome and health:
700 Where chemistry meets biology. *Science* 2020;367:392-396

701 Virolainen, S.J.; VonHandorf, A.; Viel, K.; Weirauch, M.T.; Kottyan, L.C. Gene-environment
702 interactions and their impact on human health. *Genes Immun* 2023;24:1-11

703 Virtanen, S.M.; Nevalainen, J.; Kronberg-Kippila, C.; Ahonen, S.; Tapanainen, H.; Uusitalo, L.;
704 Takkinen, H.M.; Niinisto, S.; Ovaskainen, M.L.; Kenward, M.G.; Veijola, R.; Ilonen, J.;
705 Simell, O.; Knip, M. Food consumption and advanced beta cell autoimmunity in young
706 children with HLA-conferred susceptibility to type 1 diabetes: a nested case-control
707 design. *Am J Clin Nutr* 2012;95:471-478

708 Wang, M.; Rang, O.; Liu, F.; Xia, W.; Li, Y.; Zhang, Y.; Lu, S.; Xu, S. A systematic review of
709 metabolomics biomarkers for Bisphenol A exposure. *Metabolomics* 2018;14:45

710 Weis, M. Impact of the gut microbiome in cardiovascular and autoimmune diseases. *Clin Sci*
711 (Lond) 2018;132:2387-2389

712 Wilson, J.C.; Furlano, R.I.; Jick, S.S.; Meier, C.R. Inflammatory Bowel Disease and the Risk of
713 Autoimmune Diseases. *J Crohns Colitis* 2016;10:186-193

714 Xia, J.; Wishart, D.S. MetPA: a web-based metabolomics tool for pathway analysis and
715 visualization. *Bioinformatics* 2010;26:2342-2344

716 Xu, J.; Huang, G.; Guo, T.L. Bisphenol S Modulates Type 1 Diabetes Development in Non-
717 Obese Diabetic (NOD) Mice with Diet- and Sex-Related Effects. *Toxics* 2019;7
718
719
720
721

Figure captions

Fig. 1. Summary of our work, which aimed to investigate how prenatal exposure to environmental contaminants alters the cord serum metabolome in the ABIS cohort. We used metabolomics to determine the levels of exposure to environmental contaminants and metabolites in the cord blood. Our work involved three main stages. Firstly, we examined the levels of exposure and significant differences between control (N = 268) and cases (N = 62). Secondly, we studied the associations of contaminant exposure with cord serum metabolic profiles. Finally, we investigated the impact of contaminant exposure on cord serum metabolites. Overall, our work sheds light on the effects of environmental contaminants on the cord serum metabolome, which may have implications for the future progression of autoimmune diseases.

Fig. 2. Box plots that illustrate the levels of selected contaminants in control and cases. The violin plots (A-F) on top of the box plots depict the distribution of the selected contaminants (log2 intensities). To test the mean difference between the control and cases, we conducted a Wilcoxon test. The p-values are provided to indicate the significance levels for the mean differences between the two groups for each contaminant (A-F). Specifically, $p < 0.05$ indicates statistical significance, and $p < 0.1$ suggests a trend toward significance. Overall, these results help to identify specific contaminants that may contribute to the altered cord serum metabolome in cases.

Fig. 3. Correlation plots that depict the relationships between contaminant exposure, metabolite clusters, and demographic data in controls (A) and cases (B). We used pairwise Spearman correlation to calculate the correlation coefficients between all cluster variables, contaminants, and demographic variables in the ABIS cohort. Positive and negative correlations are denoted by blue and red colours, respectively. The size of the dot in each cell corresponds to the strength of the pairwise correlation. To improve visualization, we only show correlations between +/- 0.20 to 1.0 in the plots. Overall, these correlation plots provide a comprehensive

overview of the complex relationships between environmental contaminants, metabolites, and demographic factors in the ABIS cohort.

Fig. 4. Partial correlation network in the form of a chord diagram that shows the associations between contaminant exposure, metabolite clusters, and demographic data in controls (A) and cases (B). To filter out spurious or indirect correlations between variables, we used the Debiased Sparse Partial Correlation (DSPC) algorithm (Basu et al. 2017) to only show direct correlations. We used a conservative cut-off between +/- 0.14 to 1.0 to visualize the correlations and project only correlations across groups (Contaminants, metabolite clusters, and covariates/demographic data). Positive and negative correlations are denoted by blue and red lines, respectively. Overall, this partial correlation network provides a more detailed view of the complex relationships between environmental contaminants, metabolites, and demographic factors in the ABIS cohort.

Fig. 5. Impact of environmental contaminants on cord serum metabolites. Horizontal bar plots (A, D, G) and (C, F, I) display the ranks of contaminants as predictors of metabolite clusters (PC2, PC11, and LC6) and individual metabolites (Tryptophan, 3-Chlorothieno [2,3-b]thiophene-2-carbonyl chloride, and TG(16:0/18:2/18:2)), respectively. The potential impact of contaminants on metabolite clusters or individual metabolites is determined by their rank at the top of the bar plot. The ranks are based on their absolute normalized (ridge) regression coefficients. Violin plots (B, E, H) show the levels of metabolites (clusters) associated with levels of exposure to contaminants from contaminants clusters 1 (CC1) and 3 (CC3). The violin plot represents the density of the sample within each quartile, and their distribution is represented using a box plot at the centre. Two-way ANOVA followed by post-hoc Tukey's HSD test was used to compare the mean difference between levels of metabolites (along quartiles).


Fig. 6. Pathway enrichment analysis comparing cases versus controls for Deoxynivalenol (DON) impact polar metabolites. The scatter plots depict the p-values using two different pathway maps: MFN pathway maps on the left panels and KEGG pathway maps on the right

772 panels. The pathway analysis methods Mummichog and GSEA are used on the y-axis and x-axis,
773 respectively, for both control (A, B) and cases (C, D). The size of the circle on each scatter plot
774 represents the pathway impact value. For more detailed information, such as the number of
775 metabolites in the pathways (total number/hits/significant hits) and p-values, please refer to the
776 supplementary information.

777


778

779 **Fig. 1**




780

781 **Fig. 2**




782

783 **Fig. 3**




784

785 **Fig. 4**




786

787 **Fig. 5**



788

789 **Fig. 6**



790

791

Prenatal exposure to environmental contaminants is associated with altered cord serum metabolite profiles in future immune-mediated diseases

Supplementary Material




Fig. S1. Box plots that show the levels of selected contaminants in the ABIS cohort at the individual disease levels. The violin plots (A-D) on top of the box plots illustrate the distribution of the selected contaminants (log₂ intensities). To compare multiple group means, we used the Kruskal-Wallis Test, and for pairwise comparison against the reference (Control), we used the Wilcoxon Test. The p-values are provided to indicate the significance levels for the mean differences between the two groups (control vs. cases) for each contaminant (A-D). Specifically, $p < 0.05$ indicates statistical significance, and $p < 0.1$ suggests a trend toward significance. CD, HT, IBD, JIA, and T1D refer to Celiac disease, Hypothyroidism, Crohn's disease, Juvenile Idiopathic Arthritis and Type 1 Diabetes respectively.




Fig. S2. Classification of controls and immune-mediated diseases using contaminant exposure as predictors. In panel A, the ranks of the predictors (contaminants) obtained from the Logistic ridge regression (LRR) model, adjusted by Z-Score, Maternal age and BMI, are presented. The greatest contributing contaminants (predictors) that aided in the classification of control vs. cases (mean AUC = 0.65, 95% CI: 0.63–0.67) are shown at the top of the chart. In panel B, the Receiver Operating Characteristic (ROC) and AUC values from stepwise-predictive LRR models (10-fold cross-validation) are shown. An optimal set of five contaminants (predictors) (AUC = 0.67, 95% CI: 0.66–0.68) associated with the classification of control vs. cases are presented.




Fig. S3. Association between exposure to environmental contaminants and the alteration of cord serum metabolites. The bar plots (A-F) show the linear predictors of changes in cord serum metabolite profiles, which are analysed in the form of metabolite clusters (Polar metabolite and lipid clusters). At the top of each bar plot (A-F), the most contributing contaminants (predictors) associated with selected metabolite clusters are shown. The ranks of the predictors are based on their absolute normalized (ridge) regression coefficients. The bar plots (A-D) represent the contaminant exposure as linear predictors of changes in polar metabolite clusters PC1, PC4, PC6 and PC10, while the bar plots (E-F) represent the contaminant exposure as linear predictors of changes in lipid clusters LC1 and LC3.

Table S1. List of contaminants, clusters and their level of identification based on the Metabolomics Standards Initiative (MSI).

Full name	Abbreviation	Cluster	Level of identification
Bisphenol S	BPS	CC1	Level 1
Deoxynivalenol	DON	CC1	Level 1
Monobutyl phthalate	MBP	CC1	Level 2
Perfluorodecanoic acid	PFDA	CC1	Level 1
Methylperfluorooctane sulfonamidoacetic acid	MeFOSAA	CC1	Level 2
Environmental Contaminant 1	EC1	CC1	Level 2
Environmental Contaminant 2	EC2	CC1	Level 2
α -Zearalanol	ZEL	CC1	Level 1
Ethylparaben	EP	CC2	Level 1
Methylparaben	MP	CC2	Level 1
Propylparaben	PP	CC2	Level 1
Perfluorohexanesulfonic acid Branched	PFHxSBr	CC3	Level 1
Perfluorohexanesulfonic acid	PFHxS	CC3	Level 1
Perfluorooctanoic acid Branched 1	PFOABr1	CC4	Level 1
Perfluorooctanoic acid Linear 1	PFOAL1	CC4	Level 1
Perfluorooctanoic acid Branched 2	PFOABr2	CC4	Level 1
Perfluorooctanoic acid Linear 2	PFOAL2	CC4	Level 1
Perfluorooctanesulfonic acid Branched	PFOSBr	CC4	Level 1
Perfluorooctanesulfonic acid	PFOS	CC4	Level 1
Environmental Contaminant 3	EC3	CC4	Level 2

Table S2. Two-way analysis of variance (ANOVA) for cord serum lipids (cluster LC1 to LC8) impacted by contaminants exposure (Contaminant cluster CC1 to CC4). The samples were grouped based on contaminants exposure quartiles (1 to 4) and Groups (Control/Cases). The statistical significance levels are represented by p-values ($p < 0.05$ marked bold, p -values < 0.1 in italics).

Contaminant cluster	Lipid cluster	Factor 1: Contaminant quartiles	Factor 2: Groups (Control, Cases)	Interactions F1*F2
CC1	LC1	0.291	0.203	0.467
CC1	LC2	0.271	0.674	0.568
CC1	LC3	9.59×10^{-4}	0.884	0.701
CC1	LC4	6.95×10^{-4}	0.983	0.850
CC1	LC5	0.519	<i>0.055</i>	<i>0.064</i>
CC1	LC6	0.265	0.124	0.111
CC1	LC7	2.03×10^{-2}	0.919	0.936
CC1	LC8	0.869	0.449	0.260
CC2	LC1	0.706	0.195	0.895
CC2	LC2	0.683	0.719	0.471
CC2	LC3	0.814	0.901	0.992
CC2	LC4	0.531	0.973	0.958
CC2	LC5	0.995	<i>0.071</i>	0.947
CC2	LC6	0.731	0.176	0.608
CC2	LC7	<i>0.096</i>	0.960	0.139
CC2	LC8	0.298	0.378	0.917
CC3	LC1	0.578	0.220	0.721
CC3	LC2	0.283	0.803	0.856
CC3	LC3	0.276	0.981	0.730
CC3	LC4	0.581	0.840	0.747
CC3	LC5	1.43×10^{-4}	<i>0.061</i>	0.433
CC3	LC6	3.27×10^{-3}	0.194	0.329
CC3	LC7	0.909	0.967	0.160
CC3	LC8	0.179	0.455	0.919
CC4	LC1	0.249	0.141	<i>0.074</i>
CC4	LC2	0.246	0.534	0.416
CC4	LC3	0.194	0.713	0.027
CC4	LC4	0.221	0.868	0.032
CC4	LC5	0.019	0.026	<i>0.068</i>
CC4	LC6	0.361	0.123	0.348
CC4	LC7	0.172	0.774	0.521
CC4	LC8	<i>0.095</i>	0.296	0.523

Table S3. Post-Hoc test that followed a two-way analysis of variance for cord serum lipids (cluster LC1 to LC8) affected by contaminant exposure (Contaminant cluster CC1 to CC4). The Post-Hoc Tukeys' HSD test was used for pairwise comparison between metabolite levels (along quartiles). The statistical significance levels are indicated by p-values, with values less than 0.05 marked in bold and values less than 0.1 in italics.

Contaminant cluster	Lipid cluster	Factor 1: Contaminant quartiles					
		Q2-Q1	Q3-Q1	Q4-Q1	Q3-Q2	Q4-Q2	Q4-Q3
CC1	LC1	1.000	0.379	0.762	0.371	0.755	0.925
CC1	LC2	0.407	0.820	0.271	0.905	0.994	0.785
CC1	LC3	0.317	0.106	3.68×10⁻⁴	0.942	<i>0.091</i>	0.289
CC1	LC4	0.166	<i>0.081</i>	2.38×10⁻⁴	0.988	0.156	0.292
CC1	LC5	0.991	0.904	0.866	0.980	0.711	0.467
CC1	LC6	0.216	0.659	0.911	0.864	0.585	0.962
CC1	LC7	0.759	0.154	0.018	0.675	0.204	0.837
CC1	LC8	0.988	0.870	0.915	0.971	0.987	0.999
CC2	LC1	0.929	0.952	0.992	0.665	0.988	0.849
CC2	LC2	0.957	0.633	0.864	0.903	0.993	0.977
CC2	LC3	0.986	0.935	0.992	0.788	0.926	0.990
CC2	LC4	0.993	0.694	0.943	0.523	0.839	0.952
CC2	LC5	1.000	0.998	0.998	0.997	0.997	1.000
CC2	LC6	0.968	0.798	0.745	0.968	0.946	1.000
CC2	LC7	0.148	0.989	0.325	0.277	0.975	0.516
CC2	LC8	0.995	0.341	0.640	0.483	0.786	0.961
CC3	LC1	0.609	0.625	0.862	1.000	0.971	0.975
CC3	LC2	0.807	0.220	0.914	0.731	0.995	0.585
CC3	LC3	0.870	0.943	0.729	0.997	0.277	0.384
CC3	LC4	1.000	0.985	0.756	0.977	0.787	0.539
CC3	LC5	0.216	0.343	4.93×10⁻⁵	0.994	0.048	0.024
CC3	LC6	0.490	0.273	0.001	0.979	0.101	0.231
CC3	LC7	0.999	0.983	0.986	0.953	0.998	0.893
CC3	LC8	0.299	0.702	0.174	0.910	0.991	0.772
CC4	LC1	0.969	0.655	0.629	0.376	0.353	1.000
CC4	LC2	0.759	0.826	0.178	0.999	0.718	0.646
CC4	LC3	0.863	0.462	0.167	0.903	0.573	0.932
CC4	LC4	0.812	0.727	0.157	0.999	0.620	0.718
CC4	LC5	0.984	0.215	0.139	0.101	<i>0.059</i>	0.996
CC4	LC6	0.999	0.881	0.470	0.818	0.389	0.895
CC4	LC7	0.993	0.504	0.449	0.345	0.300	1.000
CC4	LC8	0.928	0.754	0.315	0.379	<i>0.093</i>	0.886

Table S4. Two-way analysis of variance (ANOVA) for cord serum polar metabolites (cluster PC1 to PC12) impacted by contaminants exposure (Contaminant cluster CC1 to CC4). The samples were grouped based on contaminants exposure quartiles (1 to 4) and Groups (Control/Cases). The statistical significance levels are represented by p-values ($p < 0.05$ marked bold, p -values < 0.1 in italics).

Contaminant cluster	Polar metabolite cluster	Factor 1: Contaminant quartiles	Factor 2: Groups (Control, Cases)	Interactions F1*F2
CC1	PC1	$<2 \times 10^{-16}$	0.685	0.331
CC1	PC2	$<2 \times 10^{-16}$	0.022	0.516
CC1	PC3	0.780	0.237	0.380
CC1	PC4	3.11×10^{-11}	0.001	0.876
CC1	PC5	0.026	0.554	0.401
CC1	PC6	$<2 \times 10^{-16}$	0.338	0.378
CC1	PC7	0.017	0.726	0.533
CC1	PC8	<i>0.082</i>	0.963	0.533
CC1	PC9	<i>0.085</i>	0.703	0.824
CC1	PC10	1.23×10^{-11}	0.967	0.731
CC1	PC11	4.09×10^{-9}	3.98×10^{-4}	0.544
CC1	PC12	<i>0.068</i>	0.356	0.824
CC2	PC1	0.025	0.574	0.186
CC2	PC2	1.89×10^{-4}	0.097	0.817
CC2	PC3	0.836	0.250	0.723
CC2	PC4	0.021	0.004	0.637
CC2	PC5	0.338	0.498	0.789
CC2	PC6	0.001	0.236	0.446
CC2	PC7	0.006	0.735	0.122
CC2	PC8	0.006	0.631	0.091
CC2	PC9	0.718	0.577	0.250
CC2	PC10	<i>0.051</i>	0.727	0.567
CC2	PC11	0.469	0.004	0.793
CC2	PC12	0.162	0.310	0.011
CC3	PC1	2.02×10^{-6}	0.589	0.829
CC3	PC2	0.131	0.199	0.550
CC3	PC3	0.115	0.259	0.665
CC3	PC4	0.044	0.011	0.515
CC3	PC5	<i>0.095</i>	0.538	0.396
CC3	PC6	0.017	0.160	0.273
CC3	PC7	0.509	0.738	0.004
CC3	PC8	0.002	0.809	0.628
CC3	PC9	0.905	0.591	0.232
CC3	PC10	<i>0.094</i>	0.554	0.953
CC3	PC11	0.044	0.005	0.384
CC3	PC12	0.822	0.318	0.148
CC4	PC1	0.242	0.468	0.861

CC4	PC2	0.376	0.118	0.678
CC4	PC3	0.034	0.143	0.855
CC4	PC4	0.138	0.002	0.666
CC4	PC5	0.027	0.273	0.473
CC4	PC6	0.001	0.398	0.617
CC4	PC7	0.686	0.833	0.032
CC4	PC8	0.010	0.427	0.090
CC4	PC9	0.659	0.738	0.525
CC4	PC10	0.019	0.621	0.943
CC4	PC11	0.183	0.002	0.677
CC4	PC12	0.579	0.401	0.006

Table S5. Post-Hoc test that followed a two-way analysis of variance for cord serum polar metabolites (cluster PC1 to PC12) affected by contaminant exposure (Contaminant cluster CC1 to CC4). The Post-Hoc Tukeys' HSD test was used for pairwise comparison between metabolite levels (along quartiles). The statistical significance levels are indicated by p-values, with values less than 0.05 marked in bold and values less than 0.1 in italics.

Contaminant cluster	Polar metabolite cluster	Factor 1: Contaminant quartiles					
		Q2-Q1	Q3-Q1	Q4-Q1	Q3-Q2	Q4-Q2	Q4-Q3
CC1	PC1	0.002	10⁻⁸	10⁻⁸	0.021	10⁻⁸	0.006
CC1	PC2	10 ⁻⁸	10⁻⁸	10⁻⁸	0.813	10⁻⁸	0.004
CC1	PC3	1.000	0.862	0.998	0.875	0.997	0.773
CC1	PC4	4×10⁻⁷	1.84×10⁻⁴	10⁻⁸	0.571	0.357	0.020
CC1	PC5	0.494	0.653	0.014	0.995	0.362	0.242
CC1	PC6	4.76×10⁻¹⁰	9.10×10⁻¹³	8.78×10⁻¹³	9.06×10⁻⁴	5.71×10⁻⁷	0.362
CC1	PC7	0.539	0.853	0.011	0.951	0.288	0.100
CC1	PC8	0.139	0.321	0.096	0.972	0.998	0.930
CC1	PC9	1.000	0.603	0.533	0.665	0.471	0.051
CC1	PC10	2.4×10⁻⁶	7×10⁻⁷	10⁻⁸	0.993	0.155	0.262
CC1	PC11	1.71×10⁻⁵	1.93×10⁻⁴	10⁻⁸	0.950	0.346	0.127
CC1	PC12	0.922	0.918	0.218	0.581	0.564	0.052
CC2	PC1	0.072	0.035	0.690	0.992	0.543	0.375
CC2	PC2	0.998	0.938	0.003	0.869	0.006	3.40×10⁻⁴
CC2	PC3	0.978	0.798	0.988	0.957	1.000	0.936
CC2	PC4	0.707	0.974	0.020	0.918	0.252	0.064
CC2	PC5	0.615	0.288	0.877	0.944	0.966	0.737
CC2	PC6	0.066	0.075	0.913	1.000	0.011	0.012
CC2	PC7	0.812	0.522	0.158	0.113	0.621	0.004
CC2	PC8	0.116	0.013	0.011	0.844	0.814	1.000
CC2	PC9	0.988	0.990	0.851	0.923	0.963	0.685
CC2	PC10	0.721	0.669	0.548	1.000	0.085	0.070
CC2	PC11	0.806	0.501	0.998	0.958	0.886	0.610
CC2	PC12	0.883	0.898	0.463	0.481	0.887	0.140
CC3	PC1	0.967	0.002	5.92×10⁻⁵	0.008	4.08×10⁻⁴	0.850
CC3	PC2	0.125	0.585	0.240	0.790	0.989	0.929
CC3	PC3	0.734	0.495	0.076	0.981	0.506	0.748
CC3	PC4	0.473	0.509	0.983	0.026	0.272	0.741
CC3	PC5	0.924	0.109	0.292	0.359	0.664	0.960
CC3	PC6	0.633	0.325	0.009	0.956	0.199	0.464
CC3	PC7	0.987	0.919	0.721	0.764	0.512	0.977
CC3	PC8	0.820	0.030	0.005	0.229	0.065	0.940
CC3	PC9	0.994	0.996	0.886	1.000	0.965	0.957
CC3	PC10	0.114	0.619	0.149	0.737	0.999	0.803
CC3	PC11	0.601	0.443	0.866	0.034	0.185	0.891

CC3	PC12	0.997	0.800	0.986	0.893	0.999	0.943
CC4	PC1	0.479	0.196	0.713	0.945	0.983	0.794
CC4	PC2	0.988	0.939	0.710	0.994	0.508	0.359
CC4	PC3	0.597	0.854	0.383	0.174	0.025	0.859
CC4	PC4	0.994	0.975	0.229	0.908	0.139	0.453
CC4	PC5	0.981	0.146	0.060	0.302	0.147	0.982
CC4	PC6	0.806	1.000	0.019	0.820	0.001	0.018
CC4	PC7	1.000	0.761	0.934	0.726	0.914	0.980
CC4	PC8	0.637	0.065	0.011	0.565	0.217	0.922
CC4	PC9	0.997	1.000	0.678	0.999	0.801	0.730
CC4	PC10	0.976	0.036	1.000	0.102	0.972	0.035
CC4	PC11	0.918	0.716	0.738	0.975	0.347	0.165
CC4	PC12	0.925	0.998	0.867	0.859	0.505	0.931

Table S6. provides information on the pathways identified through pathway enrichment analysis using MFN pathway maps for controls. It includes the pathways, their corresponding p-values, and the number of metabolites in each pathway, including the total size, hits, and significant hits. The combined p-value was calculated by combining GSEA and Mummichog scores. This table lists only those pathways that have a combined p-value of less than 0.05.

Name of the pathways	Total size	Hits	Significant hits	Mummichog P values	GSEA P values	Combined P values
Tyrosine metabolism	160	50	40	0.0207	0.0099	0.00195
Tryptophan metabolism	94	31	26	0.02223	0.0198	0.00384
Valine, leucine and isoleucine degradation	65	12	11	0.049	0.0101	0.00426
Pyrimidine metabolism	70	20	17	0.05297	0.0099	0.00449
Urea cycle/amino group metabolism	85	26	21	0.07829	0.01	0.00638
Glycine, serine, alanine and threonine metabolism	88	27	21	0.1365	0.01	0.01037
Butanoate metabolism	34	11	10	0.06911	0.02083	0.01086
Beta-Alanine metabolism	20	9	8	0.1347	0.01099	0.01112
Caffeine metabolism	11	4	4	0.1909	0.01176	0.01594
Fructose and mannose metabolism	33	7	7	0.05475	0.04301	0.01661
Sialic acid metabolism	107	14	11	0.2462	0.01	0.01725
Aminosugars metabolism	69	10	8	0.286	0.01064	0.02068
Propanoate metabolism	31	9	8	0.1347	0.03297	0.02849
Pyruvate Metabolism	20	11	8	0.4575	0.01099	0.03164
Hexose phosphorylation	20	10	7	0.5454	0.01099	0.03667
Methionine and cysteine metabolism	94	17	14	0.1189	0.05941	0.04206
Glutamate metabolism	15	9	8	0.1347	0.05495	0.04371
Selenoamino acid metabolism	35	6	5	0.3404	0.02222	0.04451
Histidine metabolism	33	10	9	0.09685	0.08511	0.0478
Glycosphingolipid metabolism	67	20	15	0.2781	0.0297	0.04787

Table S7. provides information on the pathways identified through pathway enrichment analysis using KEGG pathway maps for controls. It includes the pathways, their corresponding p-values, and the number of metabolites in each pathway, including the total size, hits, and significant hits. The combined p-value was calculated by combining GSEA and Mummichog scores. This table lists only those pathways that have a combined p-value of less than 0.05.

Name of the pathways	Total size	Hits	Significant hits	Mummichog P values	GSEA P values	Combined P values
Aminoacyl-tRNA biosynthesis	22	14	14	0.0072	0.0101	0.00077
Glycine, serine and threonine metabolism	30	14	14	0.0072	0.0101	0.00077
Tyrosine metabolism	42	21	19	0.02887	0.0099	0.00262
Fructose and mannose metabolism	20	6	6	0.1235	0.0105 ₃	0.00994
Valine, leucine and isoleucine biosynthesis	8	6	6	0.1235	0.0105 ₃	0.00994
Valine, leucine and isoleucine degradation	35	10	9	0.158	0.0101	0.01188
Phenylalanine metabolism	10	8	7	0.2676	0.0101	0.01869
Phenylalanine, tyrosine and tryptophan biosynthesis	4	3	3	0.3529	0.0133 ₃	0.02991
Amino sugar and nucleotide sugar metabolism	35	9	6	0.7479	0.0101	0.04446

Table S8. provides information on the pathways identified through pathway enrichment analysis using MFN pathway maps for cases. It includes the pathways, their corresponding p-values, and the number of metabolites in each pathway, including the total size, hits, and significant hits. The combined p-value was calculated by combining GSEA and Mummichog scores. This table lists only those pathways that have a combined p-value of less than 0.05.

Name of the pathways	Total size	Hits	Significant hits	Mummichog P values	GSEA P values	Combined P values
Urea cycle/amino group metabolism	85	21	8	0.04279	0.0105 ₃	0.00392
Beta-Alanine metabolism	20	9	5	0.01973	0.0246 ₉	0.0042
Glutamate metabolism	15	8	4	0.05732	0.0125	0.0059
Glutathione Metabolism	19	4	3	0.02771	0.0281 ₇	0.00637
Aminosugars metabolism	69	10	5	0.03316	0.0246 ₉	0.00664
Valine, leucine and isoleucine degradation	65	11	5	0.05113	0.0232 ₆	0.0092
Alanine and Aspartate Metabolism	30	10	4	0.1235	0.0125	0.01154
Pyruvate Metabolism	20	10	4	0.1235	0.0125	0.01154
Glycerophospholipid metabolism	156	21	7	0.1102	0.0210 ₅	0.01639
Glycine, serine, alanine and threonine metabolism	88	25	7	0.2259	0.0106 ₄	0.0169
Butanoate metabolism	34	10	4	0.1235	0.0229 ₉	0.01949
Carbon fixation	10	2	2	0.04075	0.0952 ₄	0.02543
Aspartate and asparagine metabolism	114	30	6	0.591	0.0108 ₇	0.03885
Pyrimidine metabolism	70	18	6	0.1357	0.0543 ₅	0.04358
Arginine and Proline Metabolism	45	19	5	0.3361	0.0224 ₇	0.04445

Table S9. provides information on the pathways identified through pathway enrichment analysis using KEGG pathway maps for cases. It includes the pathways, their corresponding p-values, and the number of metabolites in each pathway, including the total size, hits, and significant hits. The combined p-value was calculated by combining GSEA and Mummichog scores. This table lists only those pathways that have a combined p-value of less than 0.05.

Name of the pathways	Total size	Hits	Significant hits	Mummichog P values	GSEA P values	Combined P values
Aminoacyl-tRNA biosynthesis	22	15	7	0.03758	0.0109 ₉	0.00363
Glycine, serine and threonine metabolism	30	14	6	0.08186	0.0112 ₄	0.00735
Phosphonate and phosphinate metabolism	4	2	2	0.05452	0.0322 ₆	0.01291
Alanine, aspartate and glutamate metabolism	28	12	5	0.1234	0.0344 ₈	0.02749
Glyoxylate and dicarboxylate metabolism	31	7	3	0.2106	0.0229 ₉	0.03066
Pantothenate and CoA biosynthesis	17	5	3	0.0864	0.0588 ₂	0.03193
Glycolysis or Gluconeogenesis	23	3	2	0.1385	0.0428 ₆	0.03637
Arginine and proline metabolism	37	19	4	0.6919	0.0109 ₉	0.0447